Two-year follow-up in patients treated with emphysematous lung sealant for advanced emphysema

Mordechai R. Kramer*, Yael Refaely, Nimrod Maimon, Dror Rosengarten, Oren Fruchter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Endoscopic lung volume-reduction therapy for emphysema has been associated with therapeutic responses smaller in magnitude and less durable than surgical volume reduction (LVRS). Bronchoscopic emphysematous lung sealant (ELS) therapy has been shown to produce improvements in pulmonary function similar to surgery at 1 year. This case series summarizes safety and efficacy data of all patients from the initial ELS study out to 2 years. Between 1 and 2 years, there were three all-cause adverse events requiring hospitalization. One patient went on to successful lung transplant. Improvements relative to baseline in spirometry (change in FEV 1: + 14.3 ± 33.1%; change in FVC: + 5.8 ± 23.2%) and diffusing capacity (change in diffusing capacity of the lung for carbon monoxide: + 10.6 ± 20.6%) were observed at 2 years. An exponential model fit to FEV 1 data at 6, 12, 18, and 24 months predicted improvements from a baseline of > 5% out to 4.1 years, similar to what has been reported following surgery. This report confirms longterm safety and efficacy following ELS therapy in advanced emphysema. Studies in a larger cohort are needed to define the role of ELS therapy in the treatment algorithm of patients with this condition.

Original languageEnglish
Pages (from-to)1677-1680
Number of pages4
Issue number5
StatePublished - Nov 2013
Externally publishedYes


Dive into the research topics of 'Two-year follow-up in patients treated with emphysematous lung sealant for advanced emphysema'. Together they form a unique fingerprint.

Cite this